tiprankstipranks
Advertisement
Advertisement

RNAC Stock Latest News

Cartesian Therapeutics Announces Board Member Murat Kalayoglu Resignation
Company AnnouncementsCartesian Therapeutics Announces Board Member Murat Kalayoglu Resignation
14d ago
8K
RNAC
RNAC’s Descartes-08 Moves Toward Phase 2 in Rare Muscle Disease: What Investors Should Watch
PremiumCompany Announcements
RNAC’s Descartes-08 Moves Toward Phase 2 in Rare Muscle Disease: What Investors Should Watch
1M ago
RNAC
Cartesian Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald
PremiumThe Fly
Cartesian Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald
1M ago
RNAC
Cartesian Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald
PremiumThe Fly
Cartesian Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald
1M ago
RNAC
Cartesian Therapeutics: Reaffirmed AURORA Timelines and Solid Cash Runway Underpin Needham Buy Rating and $42 Target
PremiumRatings
Cartesian Therapeutics: Reaffirmed AURORA Timelines and Solid Cash Runway Underpin Needham Buy Rating and $42 Target
1M ago
RNAC
Cartesian Therapeutics reports FY25 EPS ($5.02), consensus ($2.35)
PremiumThe FlyCartesian Therapeutics reports FY25 EPS ($5.02), consensus ($2.35)
1M ago
RNAC
RNAC Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
RNAC Upcoming Earnings Report: What to Expect?
1M ago
RNAC
Cartesian Therapeutics announces employment inducement grants
Premium
The Fly
Cartesian Therapeutics announces employment inducement grants
2M ago
RNAC
Cartesian Therapeutics Outlines 2026 Outlook and Trial Progress
PremiumCompany Announcements
Cartesian Therapeutics Outlines 2026 Outlook and Trial Progress
3M ago
8K
RNAC
Cartesian Therapeutics highlights recent progress, outlines 2026
PremiumThe Fly
Cartesian Therapeutics highlights recent progress, outlines 2026
3M ago
RNAC
Cartesian Therapeutics announces employment inducement grants
PremiumThe Fly
Cartesian Therapeutics announces employment inducement grants
3M ago
RNAC
Strategic Positioning and Unique Treatment Profile Drive Buy Rating for Cartesian Therapeutics
PremiumRatings
Strategic Positioning and Unique Treatment Profile Drive Buy Rating for Cartesian Therapeutics
4M ago
RNAC
Strategic Pivot and Promising Clinical Data Justify Buy Rating for Cartesian Therapeutics
PremiumRatingsStrategic Pivot and Promising Clinical Data Justify Buy Rating for Cartesian Therapeutics
5M ago
RNAC
H.C. Wainwright cuts Cartesian target, calls shares ‘mispriced’
Premium
The Fly
H.C. Wainwright cuts Cartesian target, calls shares ‘mispriced’
5M ago
RNAC
Strategic Realignment Boosts Cartesian Therapeutics’ Prospects: Gil Blum Issues Buy Rating
Premium
Ratings
Strategic Realignment Boosts Cartesian Therapeutics’ Prospects: Gil Blum Issues Buy Rating
5M ago
RNAC
Cartesian Therapeutics price target raised to $44 from $42 at BTIG
PremiumThe Fly
Cartesian Therapeutics price target raised to $44 from $42 at BTIG
5M ago
RNAC
Cartesian Therapeutics Reports Q3 2025 Financial Results
PremiumCompany Announcements
Cartesian Therapeutics Reports Q3 2025 Financial Results
5M ago
RNAC
Cartesian announces positive initial data from Phase 2 SLE trial of Descartes-08
PremiumThe Fly
Cartesian announces positive initial data from Phase 2 SLE trial of Descartes-08
5M ago
RNAC
Cartesian Therapeutics Reports Promising Phase 2 Trial Results
PremiumCompany Announcements
Cartesian Therapeutics Reports Promising Phase 2 Trial Results
5M ago
8K
RNAC
Cartesian Therapeutics reports Q3 EPS ($1.38) vs ($1.13) last year
PremiumThe FlyCartesian Therapeutics reports Q3 EPS ($1.38) vs ($1.13) last year
5M ago
RNAC
Cartesian Therapeutics Announces Leadership Changes
Premium
Company Announcements
Cartesian Therapeutics Announces Leadership Changes
6M ago
8K
RNAC
Cartesian Therapeutics announces employment inducement grant
Premium
The Fly
Cartesian Therapeutics announces employment inducement grant
6M ago
RNAC

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >